Citations

Clear

9383 citation(s) found for "Thomas, PS".

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
Kudva, Yogish C. , Raghinaru, Dan, Lum, John W. , Graham, Timothy E., Liljenquist, David R., Spanakis, Elias K. , Pasquel, Francisco J. , Ahmann, Andrew , Blevins, Thomas , Kruger, Davida , Brown, Sue A. , Weinstock, Ruth S. , Spaic, Tamara , Hirsch, Irl B., Broyles, Frances E. , Raskin, Philip, Desjardins, Donna, Terry, Adrienne, Singh, Lakshmi G., Davis, Georgia M. , Schmid, Caleb, Kravarusic, Jelena, Coyne, Kasey, Casaubon, Luis, Espinosa, Valerie, Jones, Jaye K., Estrada, Kathleen, Afreen, Samina , Levister, Camilla, O’Malley, Grenye , Liu, Selina , Marks, Sheryl, Peleckis, Amy J. , Tardio, Vanessa , Kurek, Corey, Luker, Ryan, Churchill, Jade, Dean, Ariel, Dennis, Brittany , Fronczyk, Evelyn, Perez, Jennifer, Mukhashen, Shereen, Dhillon, Jasmeen, Ipek, Aslihan, Bzdick, Suzan, Atakov-Castillo, Astrid , Driscoll, Marsha, Averkiou, Xenia, Dalton-Bakes, Cornelia, Moore, Adelyn, Jordan, Lin F., Lesniak, Amanda, Pinsker, Jordan E. , Sasson-Katchalski, Ravid, Campos, Tiffany, Spanbauer, Charles , Kollman, Craig, Beck, Roy W., Rickels, Michael R , Pasqua, Melissa-Rosina , Pinsker, Jordan E , Pasquel, Francisco J , Ahn, David , Aleppo, Grazia , Levy, Carol J. , Steenkamp, Devin W , Rickels, Michael R. , Tsoukas, Michael A. , Hatipoğlu, Betül , Jones, Jaye K., Marks, Sheryl, Tajrishi, Farbod Zahedi , Dean, Ariel, Moore, Adelyn, Lesniak, Amanda, Kanapka, Lauren , Kollman, Craig , Beck, Roy W.

Mayo Clinic

New England Journal of Medicine | March 19, 2025 | Volume: 392 | Issue: 18 | Pages: 1801-1812

10.1056/nejmoa2415948 | PMID 40105270 Get It

Infective endocarditis: it takes a team
Lau, Lawrence , Baddour, Larry M. , Fernández‐Hidalgo, Nuria , Brothers, Thomas D. , Kong, William , Borger, Michael A. , Duval, Xavier, Tribouilloy, Christophe , Golian, Mehrdad , Chan, Kwan L., Prendergast, Bernard , Rubens, Fraser D. , Messika–Zeitoun, David , Baddour, Larry , Prendergast, Bernard D , Messika-Zeitoun, David , Fernández-Hidalgo, Nuria , Duval, Xavier , Obadia, Jean‐François , Corrales‐Medina, Vicente , Auclair, Francois, Mazighi, Mikaël , Habib, Gilbert

Mayo Clinic

European Heart Journal | March 19, 2025 | Volume: 46 | Issue: 24 | Pages: 2275-2288

10.1093/eurheartj/ehaf219 | PMID 40214743 Get It

Abstract Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation of injection drug use in many areas of the world. In parallel, advancements in diagnostic and therapeutic options have led to complex strategies in patients’ management. Despite these epidemiologic shifts, clinical trials have been rare and most of the evidence guiding IE management derives from expert consensus or analysis of large registries. Because of this, a multi-disciplinary IE team-based approach has been recommended as the standard of care. The aim of this review is to explore the rationale for a multi-disciplinary team-based approach to the management of IE. This approach has proved to be potentially beneficial based on multiple investigations that have evaluated patient outcomes. In addition, implementation strategies, feasibility and options of the team approach have also been highlighted.
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Sorror, Mohamed L. , Saber, Wael , Logan, Brent R. , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Knight, Thomas G. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Jarrett, Lori, Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Geller, Nancy , Knight, Thomas G , Nakamura, Ryotaro , Dahi, Parastoo B , Saultz, Jennifer N , Imus, Philip H , Hogan, William J , Bhatt, Vijaya Raj , Artz, Andrew S , Sorror, Mohamed , Wood, William A. , Walston, Jeremy D , Jarrett, Lori, McCurdy, Shannon , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Artz, Andrew

Mayo Clinic

Blood Advances | March 18, 2025 | Volume: 9 | Issue: 13 | Pages: 3268-3280

10.1182/bloodadvances.2025015793 | PMID 40101246 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudo-value boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352.
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Janni, Wolfgang , Yab, Tracy C. , Cristofanilli, Massimo , Hayes, Daniel F. , Ignatiadis, Michail , Regan, Meredith M. , Alix‐Panabières, Catherine , Barlow, William E. , Gazzaniga, Paola , Gisbert‐Criado, Rafael , Jiang, Zefei , Magbanua, Mark Jesus M. , Mavroudis, Dimitriοs , Müller, Volkmar , Pierga, Jean‐Yves , Rack, Brigitte , Riethdorf, Sabine , Sleijfer, Stefan , Smerage, Jeffrey B. , Stebbing, Justin , Vidal-Martínez, José , Liu, Minetta C. , Friedl, Thomas W P , Yab, Tracy C , Bidard, Francois-Clément , Cristofanilli, Massimo , Hayes, Daniel F , Ignatiadis, Michail , Regan, Meredith M , Alix-Panabieres, Catherine , Barlow, William E , Caldas, Carlos , Carey, Lisa A , Dirix, Luc , Fehm, Tanja , García-Sáenz, José A , Gazzaniga, Paola , Generali, Daniele , Gerratana, Lorenzo , Gisbert-Criado, Rafael , Jacot, William , Jiang, Zefei , Joosse, Simon A , Lianidou, Evi , López López, Rafael , Magbanua, Mark J M , Manso Sanchez, Luis , Mavroudis, Dimitris , Müller, Volkmar , Munzone, Elisabetta , Pantel, Klaus , Pierga, Jean-Yves , Rack, Brigitte , Riethdorf, Sabine , Rugo, Hope S , Sideras, Kostandinos , Sleijfer, Stefan , Smerage, Jeffrey , Stebbing, Justin , Terstappen, Leon W M M , Vidal-Martínez, Jose , Wallwiener, Markus , Giridhar, Karthik V , Liu, Minetta , Caldas, Carlos , Carey, Lisa A. , Fehm, Tanja , García-Sáenz, José Á. , Joosse, Simon A. , Manso, Luís , Rugo, Hope S. , Sideras, Kostandinos , Terstappen, Leon W.M.M. , Giridhar, Karthik V.

Mayo Clinic

Clinical Cancer Research | March 18, 2025 | Volume: 31 | Issue: 11 | Pages: 2196-2209

10.1158/1078-0432.ccr-24-3108 | PMID 40100138 Get It

Abstract Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different breast cancer subtypes and clinical settings. Experimental Design: In total, 4,436 individual patient-level data with CTC results from both baseline and one follow-up (CellSearch; Menarini Silicon Biosystems) were analyzed to evaluate the association between CTC detection and overall survival (OS) in the full patient cohort and separately for tumor and treatment types. Results: Using the cutoff ≥1 CTC for CTC positivity, 913 (20.6%) patients had 0 CTCs at both time points (neg/neg) and 325 (7.3%) and 1,189 (26.8%) patients converted from CTC negative to CTC positive (neg/pos) or vice versa (pos/neg), whereas 2,009 (45.3%) patients had at least one CTC at both time points (pos/pos). The median OS for the neg/neg, neg/pos, pos/neg, and pos/pos group was 45.6, 26.1, 32.3, and 17.3 months, respectively (P < 0.0001, global log-rank test). CTC responders (pos/neg) showed a lower risk of death compared with CTC nonresponders (pos/pos; HR, 0.48; 95% confidence interval, 0.44–0.53). Similar results were obtained in subgroup analyses according to hormone receptor and HER2 subtype, treatment type, and with a ≥5 CTC cutoff for CTC positivity. Conclusions: Follow-up CTC assessments strongly predict OS independently from tumor subtype and treatment. New randomized trials to define the clinical utility of CTC monitoring for risk stratification and as an early response marker in metastatic breast cancer are urgently needed.
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes
Beck, Roy W. , Aktürk, Halis Kaan , Rizvi, Shafaq , Kudva, Yogish C. , Blevins, Thomas , Church, Mei Mei , Manessis, Anastasios , Calhoun, Peter , Ruedy, Katrina J., Group, for the INHALE-3 Study, Akturk, Halis K , Rizvi, Shafaq Raza , Kudva, Yogish C. , Calhoun, Peter , Hirsch, Irl B , INHALE-3 Study Group , Beck, Roy W , Hirsch, Irl B. , Group, for the INHALE-3 Study

Mayo Clinic

Diabetes Technology & Therapeutics | March 18, 2025 | Volume: 27 | Issue: 3 | Pages: 161-169

10.1089/dia.2024.0581 | PMID 40098469 Get It

Double-Blind Study Comparing Auranofin and d-Penicillamine in Rheumatoid Arthritis
Luthra, Harvinder S., Bunch, Thomas W., O’Duffy, J. Desmond, Dillon, A. M., Lakhanpal, S., O’fallon, W. M., Dillon, A. M., Lakhanpal, S., O’fallon, W. M.

Mayo Clinic

Scandinavian Journal of Rheumatology | March 17, 2025 | Volume: 15 | Issue: sup63 | Pages: 55-56

10.1080/15027732.1986.12461440 Get It

Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Sisk, Bryan A. , Eng, Whitney , Mack, Joana M. , Tran, Andrew , Ogino, Jayme , Pearson, Erika , Bies, Joshua J., Smink, Gayle , Shah, Sonal D. , Mohney, Lindsey , Fassel, Hannah, Schulte, Rachael , Tessem, Renae A., Swaminathan, Neeraja , McLean, Thomas W. , Alturky, Sara , Wu, Melinda , Atkinson, Autumn, Al‐Huniti, Ahmad , Massey, Gita , Engel, Elissa , Echols, Tyson C. , Kumar, Sumukh Arun , Fox, Michael D. , King, Katherine A., Mack, Joana , Pearson, Erika , Shah, Sonal D , Swaminathan, Neeraja , McLean, Thomas W , Blatt, Julie , Massey, Gita , Ricci, Kiersten , Echols, Tyson , Fox, Michael , Sisk, Bryan A , Aye, Jamie M. , Chang, Vivian Y. , Hogeling, Marcia , Atkinson, Autumn

Mayo Clinic

Pediatric Blood & Cancer | March 17, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31661 | PMID 40091541 Get It

ABSTRACTPatients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI
Lagarde, Julien , Blazhenets, Ganna , Zhang, J. , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Allen, Isabel Elaine , Soleimani‐Meigooni, David N. , Zeltzer, Ehud , Windon, Charles , Raya, Maison Abu , Smith, Karen, Shankar, Ranjani , Amuiri, Alinda, Rocha, Salma, Hammers, Dustin B. , Dage, Jeffrey L. , Kirby, Kala, Aisen, Paul, Koeppe, Robert, Landau, Susan, Carrillo, María C. , Touroutoglou, Alexandra , Brickhouse, Michael , Raman, Rema , Day, Gregory S. , Duara, Ranjan, Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Grant, Ian , Rogalskı, Emily , Johnson, Erik C. B. , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D. , Blazhenets, Ganna , Soleimani-Meigooni, David , Zeltzer, Ehud , Windon, Charles , Abu Raya, Maison , Vrillon, Agathe , Nudelman, Kelly N , Vemuri, Prashanthi , Day, Gregory S , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon , Wingo, Thomas S , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Maiti, Piyush , Schonhaut, Daniel R. , Hammers, Dustin B , Nudelman, Kelly , Kirby, Kala, Vemuri, Prashanthi , Beckett, Laurel , Atri, Alireza , Honig, Lawrence S. , Jones, David T., Womack, Kyle , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Neurology | March 17, 2025 | Volume: 98 | Issue: 2 | Pages: 236-248

10.1002/ana.27233 | PMID 40091774 Get It

Objective Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) differ in many respects. Here, we address the issue of possible differences in fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to the lack of large‐scale comparative studies. Methods Three hundred ninety‐nine cognitively impaired participants younger than 65 years of age from the multicenter Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and 450 cognitively impaired participants older than 65 years from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), and amyloid PET and were included in this study. We compared amyloid PET outcomes (positivity rate based on visual read and quantified tracer uptake expressed as Centiloids [CLs]) between the 2 cohorts and studied their association with age, sex, APOE genotype, and cognition. Results The amyloid positivity rate was higher in LEADS (78%, 95% confidence interval [CI] = 74–82) than in ADNI (71%, 95% CI = 67–75, p = 0.02). Lower Mini‐Mental State Examination (MMSE) and APOE4 genotype increased the odds of amyloid positivity in both cohorts. Visually positive scans had higher CLs in LEADS (EOAD, mean = 95.3 ± 26.1) than in ADNI (LOAD, mean = 80.9 ± 36.8, p < 0.0001), predominantly in parietal cortex/precuneus, superior temporal, and frontal cortices. In amyloid‐positive patients, (1) CLs were higher in female patients in both cohorts; (2) APOE4 carriership was associated with lower CLs in EOAD, which was not observed in LOAD; and (3) correlations between CLs and MMSE scores were significantly stronger in EOAD than in LOAD. Interpretation Differences in the burden of amyloid pathology may contribute to differences in clinical and anatomic patterns in sporadic EOAD and LOAD, and have implications for optimizing therapeutic strategies in each group. ANN NEUROL 2025;98:236–248
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, Meera , Hung, Kevin , Baranwal, Anmol , Al‐Kali, Aref , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Shah, Syed Naseem, Khanna, Shreyas, Ladon, Dariusz, Gannamani, Vedavyas, Begna, Kebede H. , Price, Zoe, Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Badar, Talha , Kumar, Sharad , Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Scott, Hamish S. , Mangaonkar, Abhishek A. , Hahn, Christopher N , Tefferi, Ayalew , Hiwase, Devendra , Shah, Mithun V , Kutyna, Monika M , Al-Kali, Aref , Toop, Carla , Greipp, Patricia T , Brown, Anna L , Begna, Kebede , Litzow, Mark R. , Hogan, William J , Badar, Talha , Kumar, Sharad , Patnaik, Mrinal , He, Rong , Gangat, Naseema , Scott, Hamish , Arana Yi, Cecilia , Hahn, Christopher , Arber, Daniel A , Kok, Chung H , Hiwase, Devendra , Baranwal, Anmol , Hung, Kevin , Kutyna, Monika , Chen, Dong , Price, Zoe K. , Hogan, William J. , Yeung, David , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow

Mayo Clinic

Blood Advances | March 14, 2025 | Volume: 9 | Issue: 13 | Pages: 3370-3380

10.1182/bloodadvances.2024015238 | PMID 40085954 Get It

Abstract This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF &lt;10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with &lt;5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF &lt;10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.